{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:00:12Z","timestamp":1790089212236,"version":"4.0.1"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016691","name":"Guangdong Provincial Pearl River Talents Program","doi-asserted-by":"publisher","award":["2019BT02N054"],"award-info":[{"award-number":["2019BT02N054"]}],"id":[{"id":"10.13039\/100016691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>\n                    Macrolides are widely used in diseases caused by\n                    <jats:italic>Mycoplasma<\/jats:italic>\n                    spp. The new semi-synthetic macrolide antibiotic tulathromycin is currently in wide use for the treatment of respiratory diseases of livestock. The objective of this study was to evaluate the antibacterial effect of tulathromycin against\n                    <jats:italic>Mycoplasma hyopneumoniae<\/jats:italic>\n                    using an\n                    <jats:italic>in vitro<\/jats:italic>\n                    pharmacokinetic\/pharmacodynamic (PK\/PD) model to reveal mechanisms of antibiotic resistance and to evaluate the fitness of drug-resistant strains. In this study, high performance liquid chromatography-tandem mass spectrometry was used to determine drug concentrations for the\n                    <jats:italic>in vitro<\/jats:italic>\n                    model after dosing. The peak concentrations were in the range 0.3125\u201320 \u03bcg\/mL (1 \u00d7 MIC-64 \u00d7 MIC). The ratio of the area under the concentration-time curve (AUC) over 72 h divided by the MIC (AUC\n                    <jats:sub>72h<\/jats:sub>\n                    \/MIC) had the highest correlation with the antibacterial effect of tulathromycin against\n                    <jats:italic>M. hyopneumoniae<\/jats:italic>\n                    . Tulathromycin also showed concentration-dependent antimicrobial effects and promoted the emergence of drug-resistant bacteria after being cultured for 168 h and most were mutations in 23S rRNA at site A2058G (\n                    <jats:italic>E.coli<\/jats:italic>\n                    numbering) and only a single isolate was an A2058T (\n                    <jats:italic>E.coli<\/jats:italic>\n                    numbering) mutant. In the presence of reserpine, we determined the MIC of tulathromycin, tilmicosin, tiamulin and tylosin against these drug-resistant bacteria and the strains with efflux pump mechanisms were found among the strains resistant to tilmicosin. Gene expression analysis indicated that the ABC and MATE transporter efflux pump genes RS01935, RS02670, RS01115, RS01970, RS02395 and RS03540 (MATE family efflux transporter) were up-regulated in the three strains (\n                    <jats:italic>P<\/jats:italic>\n                    &amp;lt; 0.05 or\n                    <jats:italic>P<\/jats:italic>\n                    &amp;lt; 0.01). These investigations provide guidance for clinical administration of tulathromycin and elucidate the mechanism and fitness cost of drug resistance in\n                    <jats:italic>M. hyopneumoniae<\/jats:italic>\n                    .\n                  <\/jats:p>","DOI":"10.3389\/fvets.2022.801800","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T02:30:30Z","timestamp":1644546630000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Emergence and Mechanism of Resistance of Tulathromycin Against Mycoplasma hyopneumoniae in a PK\/PD Model and the Fitness Costs of 23S rRNA Mutants"],"prefix":"10.3389","volume":"9","author":[{"given":"Xirui","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhou","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanzhong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.vetmic.2007.09.008","article-title":"Control of Mycoplasma hyopneumoniae infections in pigs","volume":"126","author":"Maes","year":"2008","journal-title":"Vet Microbiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.vetmic.2008.09.061","article-title":"Experimental infection of SPF pigs with Actinobacillus pleuropneumoniae serotype 9 alone or in association with Mycoplasma hyopneumoniae","volume":"135","author":"Marois","year":"2009","journal-title":"Vet Microbiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0034-5288(97)90010-2","article-title":"In vitro susceptibilities of recent field isolates of Mycoplasma hyopneumoniae and Mycoplasma hyosynoviae to valnemulin (Econor\u00ae), tiamulin and enrofloxacin and the in vitro development of resistance to certain antimicrobial agents in Mycoplasma hyopneumoniae","volume":"63","author":"Hannan","year":"1997","journal-title":"Res Vet Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1128\/AAC.14.2.210","article-title":"In Vitro Susceptibility of Mycoplasma hyopneumoniae andMycoplasma hyorhinis to Fifty-One Antimicrobial Agents","volume":"14","author":"Williams","year":"1978","journal-title":"Antimicrob Agents Ch."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1046\/j.1365-2958.2001.02595.x","article-title":"The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome","volume":"41","author":"Poulsen","year":"2001","journal-title":"Mol Microbiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1164\/ajrccm\/146.1.196","article-title":"Erythromycin Reduces Neutrophils and Neutrophil-derived Elastolytic-like Activity in the Lower Respiratory Tract of Bronchiolitis Patients","volume":"146","author":"Ichikawa","year":"1992","journal-title":"Am Rev Respir Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.tvjl.2013.07.032","article-title":"The role of the macrolide tulathromycin in veterinary medicine","volume":"198","author":"Villarino","year":"2013","journal-title":"Vet J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2165\/00003495-199600511-00006","article-title":"Mechanism of Action of Streptogramins and Macrolides","volume":"51","author":"Vannuffel","year":"1996","journal-title":"Drugs."},{"key":"B9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13567-021-00934-w","article-title":"The TonB system in Aeromonas hydrophila NJ-35 is essential for MacA2B2 efflux pump-mediated macrolide resistance","volume":"52","author":"Dong","year":"2021","journal-title":"Vet Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1128\/AAC.46.10.3142-3150.2002","article-title":"Mutations in 23S rRNA account for intrinsic resistance to macrolides in mycoplasma hominis and mycoplasma fermentans and for acquired resistance to macrolides in M","volume":"46","author":"Pereyre","year":"2002","journal-title":"hominis. Antimicrob Agents Ch."},{"key":"B11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3967\/bes2017.045","article-title":"Whole genome analysis reveals new insights into macrolide resistance in Mycoplasma pneumoniae","volume":"30","author":"LI SL SUN","year":"2017","journal-title":"Biomed Environ Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1471-2164-14-80","article-title":"Comparative genomic analyses of Mycoplasma hyopneumoniae pathogenic 168 strain and its high-passaged attenuated strain","volume":"14","author":"Liu","year":"2013","journal-title":"BMC Genomics."},{"key":"B13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.32607\/actanaturae.10941","article-title":"The genome structure of ciprofloxacin-resistant Mycoplasma hominis clinical isolates","volume":"12","author":"Kolesnikova","year":"2020","journal-title":"Acta Naturae."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1128\/AAC.49.10.4362-4364.2005","article-title":"AbeM, an H+ -CoupledAcinetobacter baumannii Multidrug Efflux Pump Belonging to the MATE Family of Transporters","volume":"49","author":"Su","year":"2005","journal-title":"Antimicrob agents ch."},{"key":"B15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ijantimicag.2016.04.007","article-title":"Development of efflux pump inhibitors in antituberculosis therapy","volume":"47","author":"Song","year":"2016","journal-title":"Int J Antimicrob Ag."},{"key":"B16","doi-asserted-by":"publisher","first-page":"982","DOI":"10.4014\/jmb.2003.03003","article-title":"Cloning and Functional Characterization of PutativeEscherichia coli ABC Multidrug Efflux Transporter YddA","volume":"30","author":"Feng","year":"2020","journal-title":"J Microbiol Biotechn."},{"key":"B17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/lam.13196","article-title":"Restraining the multidrug efflux transporter STY4874 ofSalmonella Typhi by reserpine and plant extracts","volume":"69","author":"Tariq","year":"2019","journal-title":"Lett Appl Microbiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1128\/AAC.46.3.672-679.2002","article-title":"Evidence of Active Efflux in Resistance to Ciprofloxacin and to Ethidium Bromide byMycoplasma hominis","volume":"46","author":"Raherison","year":"2002","journal-title":"Antimicrob Agents Ch."},{"key":"B19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/pathogens9060487","article-title":"The PK\/PD Integration and Resistance of Tilmicosin against Mycoplasma hyopneumoniae","volume":"9","author":"Huang","year":"2020","journal-title":"Pathogens"},{"key":"B20","doi-asserted-by":"publisher","first-page":"104255","DOI":"10.1016\/j.micpath.2020.104255","article-title":"Pharmacokinetic-pharmacodynamic integration and resistance of tiamulin against Mycoplasma hyopneumoniae in an in vitro dynamic model","volume":"147","author":"Huang","year":"2020","journal-title":"Microb pathogenesis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1021\/cb300105p","article-title":"Visualizing the 16-Membered Ring Macrolides Tildipirosin and Tilmicosin Bound to Their Ribosomal Site","volume":"7","author":"Poehlsgaard","year":"2012","journal-title":"Acs Chem Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7164\/antibiotics.57.280","article-title":"In Vitro microbiological characterization of a novel azalide, two triamilides and an azalide ketal against bovine and porcine respiratory pathogens","volume":"57","author":"NORCIA LJL SILVIA","year":"2004","journal-title":"J Antibiot."},{"key":"B23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3390\/antibiotics9060313","article-title":"Tiamulin-Resistant Mutants of the Thermophilic Bacterium Thermus thermophilus","volume":"9","author":"Killeavy","year":"2020","journal-title":"Antibiotics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/jac\/47.3.277","article-title":"Fitness and competitive growth advantage of new gentamicin-susceptible MRSA clones spreading in French hospitals","volume":"47","author":"Laurent","year":"2001","journal-title":"J Antimicrob Chemoth."},{"key":"B25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1369-5274(99)00005-3","article-title":"The biological cost of antibiotic resistance","volume":"2","author":"Andersson","year":"1999","journal-title":"Curr Opin Microbiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12866-019-1478-7","article-title":"Rifampin resistance and its fitness cost in Riemerella anatipestifer","volume":"19","author":"Sun","year":"2019","journal-title":"BMC Microbiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1089\/mdr.2009.0008","article-title":"23S rRNA mutation A2074C conferring high-level macrolide resistance and fitness cost in Campylobacter jejuni","volume":"15","author":"Hao","year":"2009","journal-title":"Microb Drug Resist"},{"key":"B28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1051\/vetres:2000100","article-title":"Guidelines and recommendations for antimicrobial minimum inhibitory concentration (MIC) testing against veterinary mycoplasma species","volume":"31","author":"Hannan","year":"2000","journal-title":"Vet Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S0034-5288(18)31146-9","article-title":"In Vitro evaluation of various quinolone antibacterial agents against veterinary mycoplasmas and porcine respiratory bacterial pathogens","volume":"46","author":"Hannan","year":"1989","journal-title":"Res Vet Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e220350","DOI":"10.1371\/journal.pone.0220350","article-title":"Analysis of the mutant selection window and killing of Mycoplasma hyopneumoniae for doxycycline, tylosin, danofloxacin, tiamulin, and valnemulin","volume":"15","author":"Huang","year":"2020","journal-title":"PLoS ONE."},{"key":"B31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1365-3164.2009.00856.x","article-title":"New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach","volume":"20","author":"Blondeau","year":"2009","journal-title":"Vet dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/jvp.12259","article-title":"The influence ofActinobacillus pleuropneumoniae infection on tulathromycin pharmacokinetics and lung tissue disposition in pigs","volume":"39","author":"Gajda","year":"2016","journal-title":"J Vet Pharmacol Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"7170","DOI":"10.1128\/AAC.04955-14","article-title":"Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using anIn Vitro Infection Model","volume":"59","author":"VanScoy","year":"2015","journal-title":"Antimicrob agents ch."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/jac\/dky045","article-title":"Elucidation of the pharmacokinetic\/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model","volume":"73","author":"Bilal","year":"2018","journal-title":"J Antimicrob Chemoth."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e01756","DOI":"10.1128\/AAC.01756-16","article-title":"UsingIn Vitro Dynamic Models To Evaluate Fluoroquinolone Activity against Emergence of Resistant Salmonella enterica Serovar Typhimurium","volume":"61","author":"Lee","year":"2017","journal-title":"Antimicrob Agents Ch"},{"key":"B36","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1089\/mdr.2005.11.290","article-title":"Characterization of In Vivo Acquired Resistance of Mycoplasma hyopneumoniae to Macrolides and Lincosamides","volume":"11","author":"Stakenborg","year":"2005","journal-title":"Microb Drug Resist."},{"key":"B37","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.1128\/JB.187.21.7548.2005","article-title":"Swine and Poultry Pathogens: the Complete Genome Sequences of Two Strains ofMycoplasma hyopneumoniae and a Strain of Mycoplasma synoviae","volume":"187","author":"Vasconcelos","year":"2005","journal-title":"J Bacteriol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1089\/mdr.2017.0254","article-title":"Macrolide-Resistance Selection in Tibetan Pigs with a High Load of Mycoplasma hyopneumoniae","volume":"24","author":"Qiu","year":"2018","journal-title":"Microb Drug Resist"},{"key":"B39","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2\u2013\u0394\u0394CT Method","volume":"25","author":"Livak","year":"2001","journal-title":"METHODS."},{"key":"B40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2144\/05391RV01","article-title":"Real-time PCR for mRNA quantitation","volume":"39","author":"Wong","year":"2005","journal-title":"Biotechniques."},{"key":"B41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/107662902760190617","article-title":"Evolutionary Barriers to Quinolone Resistance in Streptococcus pneumoniae","volume":"8","author":"Gillespie","year":"2002","journal-title":"Microb Drug Resist."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e209177","DOI":"10.1371\/journal.pone.0209177","article-title":"Pharmacokinetic\/pharmacodynamic (PK\/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model","volume":"13","author":"Zhao","year":"2018","journal-title":"PLoS ONE."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00392","article-title":"Pharmacokinetic\/Pharmacodynamic Modeling of Tulathromycin against Pasteurella multocida in a porcine tissue cage model","volume":"8","author":"Zhou","year":"2017","journal-title":"Front Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3389\/fphar.2017.00684","article-title":"Pharmacodynamic Evaluation and PK\/PD-Based Dose Prediction of Tulathromycin: A Potential New Indication for Streptococcus suis Infection","volume":"8","author":"Zhou","year":"2017"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1128\/AAC.48.8.2853-2860.2004","article-title":"Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a Model of J774 Mouse Macrophages","volume":"48","author":"Van Bambeke","year":"2004","journal-title":"ANTIMICROB AGENTS CH."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e00686","DOI":"10.1128\/AAC.00686-18","article-title":"Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia","volume":"62","author":"Zheng","year":"2018","journal-title":"Antimicrob Agents Ch"},{"key":"B47","first-page":"137","article-title":"Clarithromycin and azithromycin: new macrolide antibiotics","volume":"11","author":"Piscitelli","year":"1992","journal-title":"Clin Pharm."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00670","article-title":"Pharmacokinetic and pharmacodynamic integration and resistance analysis of tilmicosin against mycoplasma gallisepticum in an in vitro dynamic model","volume":"10","author":"Huang","year":"2019","journal-title":"Front pharmacol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41429-017-0016-9","article-title":"Time inside the mutant selection window as a predictor of staphylococcal resistance to linezolid","volume":"71","author":"Alieva","year":"2018","journal-title":"J Antibiot."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e202070","DOI":"10.1371\/journal.pone.0202070","article-title":"Relationship between danofloxacin PK\/PD parameters and emergence and mechanism of resistance of Mycoplasma gallisepticum in In Vitro model","volume":"13","author":"Zhang","year":"2018","journal-title":"PLoS ONE."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e02267","DOI":"10.1128\/mBio.02267-16","article-title":"ATP-Dependent Persister Formation in Escherichia coli","volume":"8","author":"Shan","year":"2017","journal-title":"MBIO"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e00249","DOI":"10.1128\/JB.00249-18","article-title":"Relationship between the Viable but Nonculturable State and Antibiotic Persister Cells","volume":"200","author":"Ayrapetyan","year":"2018","journal-title":"J Bacteriol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1126\/science.aaj2191","article-title":"Antibiotic tolerance facilitates the evolution of resistance","volume":"355","author":"Levin-Reisman","year":"2017","journal-title":"Science."},{"key":"B54","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1292\/jvms.15-0541","article-title":"Differential diagnosis of [[i]]Brucella abortus[[\/i]] by real-time PCR based on a single-nucleotide polymorphisms","volume":"78","author":"KIM","year":"2016","journal-title":"J Vet Med Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/cid\/ciz1031","article-title":"Resistance-Guided Antimicrobial Therapy Using Doxycycline\u2013Moxifloxacin and Doxycycline\u221225 g Azithromycin for the Treatment of Mycoplasma genitalium Infection: Efficacy and Tolerability","volume":"71","author":"Durukan","year":"2020","journal-title":"Clin Infect Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.3201\/eid2608.191806","article-title":"Doxycycline and Sitafloxacin Combination Therapy for Treating Highly Resistant Mycoplasma genitalium","volume":"26","author":"Durukan","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jgar.2017.09.018","article-title":"Macrolide resistance in Mycoplasma genitalium from female sex workers in Belgium","volume":"12","author":"Coorevits","year":"2018","journal-title":"J GLOB ANTIMICROB RE."},{"key":"B58","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1292\/jvms.15-0304","article-title":"Antimicrobial susceptibility and molecular characterization of macrolide resistance of Mycoplasma bovis isolates from multiple provinces in China","volume":"78","author":"Kong","year":"2016","journal-title":"J Vet Med Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.vetmic.2018.02.014","article-title":"23S rRNA and L22 ribosomal protein are involved in the acquisition of macrolide and lincosamide resistance in Mycoplasma capricolum subsp. capricolum","volume":"216","author":"Prats-van Der Ham","year":"2018","journal-title":"Vet Microbiol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.femsle.2005.05.012","article-title":"Induction of macrolide resistance in Mycoplasma gallisepticum in vitro and its resistance-related mutations within domain V of 23S rRNA","volume":"247","author":"Wu","year":"2005","journal-title":"Fems Microbiol Lett."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e202428","DOI":"10.1371\/journal.pone.0202428","article-title":"Mycoplasma genitalium in the Far North Queensland backpacker population: An observational study of prevalence and azithromycin resistance","volume":"13","author":"Trevis","year":"2018","journal-title":"PLoS ONE."},{"key":"B62","first-page":"209","article-title":"Resistance to azithromycin of Neisseria gonorrhoeae strains isolated in Poland in) 2012-2013 years","volume":"66","author":"M\u0142ynarczyk-Bonikowska","year":"2014","journal-title":"Medycyna do\u015bwiadczalna i mikrobiologia."},{"key":"B63","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1574-6968.2010.02003.x","article-title":"Mutations in 23S rRNA gene associated with decreased susceptibility to tiamulin and valnemulin in Mycoplasma gallisepticum","volume":"308","author":"Li","year":"2010","journal-title":"Fems Microbiol Lett"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mimet.2012.07.005","article-title":"Identification and validation of reference genes to study the gene expression in Gluconacetobacter diazotrophicus grown in different carbon sources using RT-qPCR","volume":"91","author":"Galisa","year":"2012","journal-title":"J Microbiol Meth."},{"key":"B65","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/jac\/dky438","article-title":"Neisseria gonorrhoeae 23S rRNA A2059G mutation is the only determinant necessary for high-level azithromycin resistance and improvesin vivo biological fitness","volume":"74","author":"Zhang","year":"2019","journal-title":"J Antimicrob Chemoth."},{"key":"B66","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1073\/pnas.0501598102","article-title":"23S rRNA base pair) 2057-2611 determines ketolide susceptibility and fitness cost of the macrolide resistance mutation) 2058A->G","volume":"102","author":"Pfister","year":"2005","journal-title":"Proc Nat Acad Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e94503","DOI":"10.1371\/journal.pone.0094503","article-title":"Identification of a Novel G2073A Mutation in 23S rRNA in Amphenicol-Selected Mutants of Campylobacter jejuni","volume":"9","author":"Ma","year":"2014","journal-title":"PLoS ONE."}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2022.801800\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T02:30:38Z","timestamp":1644546638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2022.801800\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":67,"alternative-id":["10.3389\/fvets.2022.801800"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2022.801800","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]},"article-number":"801800"}}